China’s Clover Biopharmaceuticals Ltd. (02197.HK) was finally looking to the future after a big bet on Covid vaccines failed to pay off. However, decisions made early on in the pandemic are still casting a long shadow.
曾經(jīng)風(fēng)光無限的“疫苗明星股”三葉草生物制藥有限公司（2197.HK），在經(jīng)歷新冠疫苗商業(yè)化失利、裁員近50%后，近期因遭全球疫苗免疫聯(lián)盟（Gavi）追討2.24億美元預(yù)付款，再次被推上風(fēng)口浪尖。
您已閱讀4%（316字），剩余96%（7834字）包含更多重要信息，訂閱以繼續(xù)探索完整內(nèi)容，并享受更多專屬服務(wù)。